skip to content

Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.